FibroGen ’s antibody fails PhIII in Duchenne muscular dystrophy

Fi­bro­Gen’s top an­ti­body can­di­date has failed a Phase III study in Duchenne mus­cu­lar dy­s­tro­phy, mark­ing a dis­ap­point­ing start to a string of read­outs slat­ed for the next few months. Dubbed pam­revlum­ab, the drug is list­ed as a lead can­di­date for Fi­bro­Gen along­side…#dubbedpamrevlumab #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news